

3 June 2026

## New Independent Director to Strengthen Board and Support Next Phase of Growth

### Key Highlights

- Edward Myer to be appointed as Non-Executive Director of Bioxyne. Mr. Myer will also be appointed the independent chair of the Audit and Finance Committee
- The appointment strengthens Bioxyne's governance, financial markets and strategic investment capability
- Edward Myer has significant board, governance and strategic development experience.
- Appointment supports independent governance across the Audit and Finance Committee and Remuneration Committee

**Bioxyne Limited (ASX: BXN) ("Bioxyne" or "the Company")**, is pleased to announce the appointment of Edward Myer as an independent Non-Executive Director of the Company.

Ed Myer, brings more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spans investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development.

The appointment comes at an important stage in Bioxyne's growth and continues to strengthen the Company's corporate governance to support its next phase of development.

Mr Myer's appointment, will support the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees.

### **Bioxyne Chairman Tony Ho commented:**

*"We are very pleased to welcome Ed to the Bioxyne Board. Ed brings extensive experience across financial markets, technology, healthcare and strategic investment, together with a strong track record of identifying and backing high-quality growth businesses."*

**ENDS**



## About the Appointee

Ed Myer is an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he has been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He has worked extensively with global investment banks across capital markets in London, Hong Kong and Australia.

Ed holds a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and is a graduate member of the Australian Institute of Company Directors.

The appointment of Mr Myer will take immediate effect following completion of the required documentation and checks. In accordance with the ASX Listing Rules. Mr Myer will stand for election by shareholders at the Company's next Annual General Meeting.

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

### **Bioxyne Limited**

Tony Ho  
Chairman  
info@bioxyne.com

### **NWR Communications**

Melissa Tempra  
Media & Investor Relations  
melissa@nwrcommunications.com.au

## About Bioxyne Ltd.

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.



## About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Scotland (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of the Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognised for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription-only medicines.
- b) Contract medicine manufacture and white label manufacture of medicinal products for human use.
- c) Wholesale distribution, import and export of controlled drugs, finished medicinal products, and active pharmaceutical ingredients.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

**United Kingdom:** [drwatsoncbd.com](https://drwatsoncbd.com)

**UK / EU:** [breathelifesciences.com](https://breathelifesciences.com)

- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: [bioxyne.com](https://bioxyne.com)

Australia: [bls.com.au](https://bls.com.au)

International: [breathelifesciences.com](https://breathelifesciences.com)